Business Update and Appendix 4C
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
22 OCTOBER 2015
BUSINESS UPDATE AND SEPTEMBER QUARTER CASHFLOW
COGSTATE RECORDS POSITIVE EBIT IN FIRST QUARTER AND REAFFIRMS GUIDANCE FOR
POSITIVE EBIT FOR 2016 FINANCIAL YEAR1
SUMMARY
Revenue of A$6.1m realised in September quarter 2015, up 80% on September
quarter 2014, albeit down 12% on the record achieved in the June quarter 2015.
Second largest quarter of new contract signings at US$8.4m (which was the
largest in A$ terms at A$11.7m). The value of quarterly contracts signed has
exceeded quarterly revenue for the last five consecutive quarters.
Since 30 September 2015, additional sales contracts totalling US$1.2m have
been signed; taking the total contracts signed YTD to US$9.6m.
Record pipeline of contracted clinical trials revenue totalling A$35.4m (PCP
A$21.2m), of which A$18.7m (PCP A$9.6m) will be recognised in FY16.
2
A Net Operating Cash Outflow of -A$0.76m in September quarter due to a
reduction in payables and the typical lags between sales and cash inflow.
September quarter 2015 saw a return to positive EBIT. Guidance for positive
FY16 EBIT maintained (compared to -A$3.05m in FY15 pre asset impairments),
with positive EBIT also expected in 1H16.
1
Cogstate (ASX.CGS) has today released a business update and its Appendix 4C – Quarterly Cash
Flow statement for the quarter ended 30 September 2015. The company reiterates its guidance for a
1
return to positive EBIT in FY16, with positive EBIT also expected in 1H16.
HIGHLIGHTS FOR THE PERIOD ENDED 30 SEPTEMBER 2015 (1Q16):
A substantial increase in year-on-year revenue: Underlying revenue for 1Q16 of A$6.1m
(excludes pass-through cost recoveries) was up 80% on 1Q15 but down 12% on the record
4Q15. Including pass-through cost recoveries; headline revenue of A$7.6m in 1Q16 was up
102% on A$3.8m reported in 1Q15. Further details provided in the results table on Page 3.
Second largest quarter of new sales contract signings: Cogstate signed US$8.4m (which
was a record in A$ terms of A$11.7m) of new Clinical Trials sales contracts in 1Q16, up 8.0%
on US$7.8m (A$9.9m) in 4Q15. This was the largest quarter of new contract signings since
3
the all time high of US$10.8m (A$11.5m) in 1Q15.
_____________________________________________________________________________________________________
1.
2.
3.
FY16 guidance based on EBIT from continuing operations at 30 June 2015 exchange rates. FY15 EBIT of -$A3.05m
excludes -$A2.16m impairment of assets.
Contracts are denominated in US$. Spot rate at the relevant date has been used to calculate the A$ equivalent.
Contracts are denominated in US$. The A$ equivalent is based on the prevailing spot rate at the time of signing the
individual contracts.
New contract signings in 1Q16 of A$11.7m exceeded the A$5.8m of Clinical Trials revenue
booked in the same period by 2.02x (Book-to-Bill ratio). This is the fifth consecutive quarter
where new contract signings have exceeded revenue (Book to Bill ratio >1), indicating growth
in the revenue pipeline.
Record revenue pipeline: At 22 October 2015, Cogstate had A$35.4m (PCP A$21.2m) of
contracted clinical trials revenue to be recognised in future periods, of which A$18.7m (PCP
A$9.6m) will be recognised in FY16. As in the past, Cogstate expects that total revenue in
FY16 will exceed the amount contracted for that year as at 22 October 2015. For example,
63% of the A$15.2m clinical trials revenue for FY15 was contracted at 22 October 2014 – see
table below for more detail.
Contracted Clinical Trials – Revenue
As at 22 Oct 2015
Year 1
FY16
A$18.7m
Year 2
FY17
A$9.2m
Years 3-5
FY18A$7.5m
FY20
Total
A$35.4m
4
As at 30 Jun 2015
FY16
A$10.9m
FY17
A$6.5m
FY18A$4.0m
FY20
A$21.4m
As at 22 Oct 2014
FY15
A$9.6m
FY16
A$4.7m
FY17A$6.9m
FY20
A$21.2m
A return to positive EBIT: Cogstate achieved a positive EBIT in the September quarter.
Excluding the A$2.2m impairment of intangible assets in June 2015, Cogstate has achieved
st
five consecutive months of positive EBIT, since 1 May 2015. In achieving positive EBIT, all
software development costs have been expensed in line with company policy and Intangible
Assets remain unchanged at the 30 June 2015 balance.
Cost control: The first quarter saw Gross Profit margins within Management’s target of 57%60%. On a constant currency basis, Management expect FY16 overhead costs to remain
broadly in line with the levels of 2H15 (annualised).
A Net Operating Cash outflow in the September quarter: Cogstate reported a Net
Operating Cash outflow of -A$0.76m in the quarter ended 30 September 2015. While this
was an improvement on the -A$1.4m recorded in the previous corresponding period, it was
down on the A$0.2m recorded in the June 2015 quarter. This was largely due to a reduction
in payables at 30 September and the typical lags between higher sales and cash inflow.
Further details provided in the results table on Page 3.
Key drivers of improving business momentum:
o Fully resourced commercial sales team (initiated October 2014 and all positions now
filled);
o Favourable industry trends driving increased demand, including
Increased trial activity looking at early stage disease in Alzheimer’s /
Dementia;
New regulatory requirements for cognition testing in Paediatrics;
Increased research activity in major psychiatric disorders
o Exit of Axon Sports, completed 30 November 2014.
Maintain prior guidance for a return to positive EBIT from continuing operations in
FY16, with positive EBIT also expected in 1H16.
_____________________________________________________________________________________________________
4. Contracts are denominated in US$. Spot rate at 30 June has been used to calculate the A$ equivalent. The rate used at 22
October 2015 was 0.732, the rate used at 30 June 2015 was 0.763 and the rate used at 22 October 2014 was 0.90.
Quarterly Report – 30 September 2015
Summary Financial Table
Revenue
Clinical Trials revenue
Other Revenue (incl. Precision
Recruitment)
Sub-total
Quarter Just
Completed
Previous
Quarter
Previous
Corresponding
Quarter
30-Sep-15
A$ million
30-Jun-15
A$ million
30-Sep-14
A$ million
5.79
6.67
2.91
0.30
0.22
0.48
6.09
6.89
3.39
Pass-through Cost Recoveries
1.51
1.24
0.38
Total Revenue
7.60
8.13
3.77
Receivables
Opening balance
Closing balance
Net Increase in Receivables
4.90
6.14
1.24
2.72
4.90
2.18
2.77
3.14
0.37
Payables
Opening balance
Closing balance
Net Reduction in Payables
(3.42)
(2.80)
0.62
(3.53)
(3.42)
0.11
(2.03)
(2.43)
(0.40)
Cash Flow
Cash receipts from customers
Cash payments to employees
Cash payments to suppliers
Cash receipts, non-trading
Net Operating Cash In/(Out) Flows
6.81
(4.68)
(2.90)
0.01
(0.76)
6.30
(4.01)
(2.57)
0.49
0.21
3.35
(2.76)
(2.01)
0.02
(1.40)
Net Investing Cash In/(Out) Flows
Net Financing Cash In/(Out) Flows
(0.38)
0.00
(0.23)
2.04
(0.23)
0.02
(1.14)
2.02
(1.61)
Net Increase/(Decrease) in cash held
(net of foreign exchange movements)
For further information contact:
Brad O’Connor
Cogstate Chief Executive Officer
+613 9664 1300 or 0411 888 347
boconnor@cogstate.com
Kyahn Williamson
Buchan Consulting
0401 018 828
kwilliamson@buchanwe.com.au
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Rule 4.7B
Rule 4.7B
Appendix 4C
Quarterly report
for entities admitted
on the basis of commitments
Introduced 31/3/2000. Amended 30/9/2001
Name of entity
Cogstate Limited
ABN
Quarter ended (“current quarter”)
80 090 975 723
30 September 2015
Consolidated statement of cash flows
Current quarter
$A
6,809,675
Year to date
(3 months)
$A
6,809,675
(a) staff costs (incl R&D)
(b) advertising and marketing
(c) research and development
(direct external costs)
(d) leased assets
(e) other working capital
(4,684,433)
(164,463)
(29,216)
(4,684,433)
(164,463)
(29,216)
(191,205)
(2,023,618)
(191,205)
(2,023,618)
Dividends received
Interest and other items of a similar nature
received
Interest and other costs of finance paid
Income taxes paid
Other (provide details if material)
Accounting & Audit
Computer costs
Legal Costs, including patent costs
Listing fees & assoc. costs
Travel costs
Grant Income
14,643
14,643
(1,875)
31,275
(1,875)
31,275
(11,001)
(99,436)
(13,605)
(32,364)
(365,735)
2,889
(11,001)
(99,436)
(13,605)
(32,364)
(365,735)
2,889
Net operating cash flows
(758,567)
(758,567)
Cash flows related to operating activities
1.1
Receipts from customers
1.2
Payments for
1.3
1.4
1.5
1.6
1.7
+ See chapter 19 for defined terms.
30/9/2001
Appendix 4C Page 4
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Current quarter
$A
Year to date
(3 months)
$A
(758,567)
(758,567)
(377,041)
-
(377,041)
-
Proceeds from disposal of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
-
-
Loans to other entities
Loans repaid by other entities
Other (provide details if material)
-
-
(377,041)
(377,041)
(1,135,608)
(1,135,608)
-
-
Net increase (decrease) in cash held
(1,135,608)
(1,135,608)
1.21
1.22
Cash at beginning of quarter/year to date
Exchange rate adjustments to item 1.20
5,444,943
(189,355)
5,444,943
(189,355)
1.23
Cash at end of quarter
4,119,980
4,119,980
1.8
1.9
1.10
1.11
1.12
1.13
Net operating cash flows (carried forward)
Cash flows related to investing activities
Payment for acquisition of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
Net investing cash flows
1.14
Total operating and investing cash flows
1.15
1.16
1.17
1.18
1.19
1.20
Cash flows related to financing activities
Proceeds from issues of shares, options, etc.
Proceeds from sale of forfeited shares
Proceeds from borrowings – convertible notes
Repayment of borrowings
Dividends paid
Other (provide details if material)
Net financing cash flows
+ See chapter 19 for defined terms.
30/9/2001
Appendix 4C Page 5
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities
Current quarter
$A
1.24
Aggregate amount of payments to the parties included in item 1.2
1.25
Aggregate amount of loans to the parties included in item 1.11
1.26
Explanation necessary for an understanding of the transactions
81,938
Nil
N/A
Non-cash financing and investing activities
2.1
Details of financing and investing transactions which have had a material effect on consolidated
assets and liabilities but did not involve cash flows
N/A
2.2
Details of outlays made by other entities to establish or increase their share in businesses in which
the reporting entity has an interest
N/A
Financing facilities available
Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
3.1
Loan facilities
3.2
Credit standby arrangements
Amount available
$A
$500,000
Amount used
$A
Nil
N/A
N/A
+ See chapter 19 for defined terms.
30/9/2001
Appendix 4C Page 6
Share your feedback
Discover